Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Onesource's partner, Dr. Reddy's Laboratories, received Health Canada approval for generic Semaglutide Injection. Onesource will serve as the CDMO partner for scale-up and commercial manufacturing from its US-FDA approved facility in Bengaluru.
Apr 29 2026 09:04:00
Onesource Specialty Pharma Limited
OneSource's Sterile Product Division in Bangalore received an EU GMP Certificate from German authorities. This certification confirms compliance with EU GMP requirements for sterile products, ensuring quality for small volume liquids and testing.
Apr 28 2026 21:04:00
Onesource Specialty Pharma shares gain after equity worth ₹408 crore changes hands in block deals
Onesource Specialty Pharma's partner has received USFDA approval for a generic version of Ozempic, a development that is expected to create new contract manufacturing opportunities for Onesource, impacting its contract development and manufacturing organization (CDMO) services positively.
Apr 21 2026 11:04:00
Onesource Specialty Pharma partner wins tentative USFDA nod for generic Ozempic; Stock falls
OneSource Specialty Pharma has received regulatory approval from Saudi Arabia for its generic version of Ozempic (semaglutide) and will commercialize it with its partner Hikma Pharmaceuticals in the Middle East and North Africa region, leveraging a significant growth opportunity in the GLP-1 market.
Apr 21 2026 09:04:00
Onesource Specialty Pharma Limited
OneSource's partner Orbicular secured tentative U.S. FDA approval for generic Ozempic® (Semaglutide Injection). OneSource acted as the CDMO partner, providing end-to-end manufacturing capabilities. This reinforces OneSource's position in complex pharmaceutical products.
Apr 21 2026 08:04:00
Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
OneSource Specialty Pharma's partner Orbicular secured tentative U.S. FDA ANDA approval for generic Ozempic® (Semaglutide Injection). OneSource acted as the CDMO partner, utilizing its US-FDA approved manufacturing site in Bangalore for production.
Apr 21 2026 08:04:00
Onesource Specialty Pharma Limited
OneSource Specialty Pharma Ltd successfully renewed its EU-GMP certification for its Bengaluru Unit II manufacturing facility. This certification validates the facility's capabilities in integrated biologics drug-substance and drug-product manufacturing, including sterile injectable products, following an inspection by a European regulatory authority.
Apr 17 2026 19:04:00
Onesource Specialty Pharma Ltd - 544292 - Intimation Of "Renewal Of EU -GMP Certification For Onesource : Flagship Unit II Facility
OneSource Specialty Pharma Ltd secured the renewal of its EU-GMP certification for its Flagship Unit II manufacturing facility in Bengaluru. This certification ensures continued compliance for its integrated biologics drug-substance and drug-product manufacturing site.
Apr 17 2026 19:04:00
Onesource Specialty Pharma Limited
OneSource Specialty Pharma Limited received an independent ESG rating of '73' (Leader category) from NSE Sustainability for FY25. The rating was based on publicly available information and not through direct company engagement.
Apr 16 2026 10:04:00
Onesource Specialty Pharma Ltd - 544292 - Intimation Of ESG Rating
OneSource Specialty Pharma Limited received an independent ESG rating of '73' (Leader category) from NSE Sustainability for FY25. The rating was independently assigned based on publicly available information.
Apr 16 2026 10:04:00
Read More